Off-Label Prescribing: A Call for Heightened Professional and Government Oversight
Authors:
- 1 January 2009
- journal article
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 37 (3) , 476-486
Abstract
Off-label prescribing is an integral part of contemporary medicine. Many patients benefit when they receive drugs or devices under circumstances not specified on the label approved by the Food and Drug Administration (FDA). An off-label use may provide the best available intervention for a patient, as well as the standard of care for a particular health problem. In oncology, pediatrics, geriatrics, obstetrics, and other practice areas, patient care could not proceed without off-label prescribing. When scientific and medical evidence justify off-label uses, physicians promote patients’ interests by prescribing products off label.Off-label prescribing can also harm patients, however. The potential for harm is greatest when an offlabel use lacks a solid evidentiary basis. A 2006 study examining prescribing practices for 169 commonly prescribed drugs found high rates of off-label use with little or no scientific support. Researchers examining off-label use in U.S. children’s hospitals concluded, “[W]e still have incomplete knowledge about the safety and efficacy of many medications commonly used to treat children across a range of drug classes and clinical diagnoses.”Keywords
This publication has 56 references indexed in Scilit:
- Off-Label Promotion, On-Target SalesPLOS Medicine, 2008
- Lipid Screening and Cardiovascular Health in ChildhoodPediatrics, 2008
- Peer-Reviewed Publication of Clinical Trials Completed for Pediatric ExclusivityJAMA, 2006
- Reimbursement for Cancer Treatment: Coverage of Off-Label Drug IndicationsJournal of Clinical Oncology, 2006
- United States Medical Practice SummaryAmerican Journal of Medical Quality, 2006
- Adopting Orphan Drugs — Two Dozen Years of Treating Rare DiseasesNew England Journal of Medicine, 2006
- Ethics and pharmaceutical medicine - the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UKInternational Journal Of Clinical Practice, 2006
- Uses of Drugs Not Described in the Package Insert (Off-Label Uses)Pediatrics, 2002
- Thalidomide as an anti‐cancer agentJournal of Cellular and Molecular Medicine, 2002
- The Architecture of Government Regulation of Medical ProductsVirginia Law Review, 1996